๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-06-09

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) (NCT07637734)

COVE-3: A Phase 3, Double-blind, Randomized, Vehicle-controlled Study to Evaluate the Efficacy and Safety of YCANTH (VP-102/TO-208) in Subjects With Common Warts (Verruca Vulgaris)

๐ŸŸก Not Yet Recruiting Phase3 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Verrica Pharmaceuticals Inc.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.

Who can join: Review the eligibility criteria below.

Location: DelRicht Research โ€” Overland Park, Kansas

Age range: 2 Years

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (2 Sites)

  • DelRicht Research โ€” Overland Park, Kansas
  • DelRicht Research โ€” Baton Rouge, Louisiana

๐Ÿ“ž Contact the Study Coordinator

Phone: (484) 453-3295

Email: 17339-COVE3@allucent.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Common Warts

Explore by condition: All Common Warts clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—